*0011151296
*008111216s2011    xx#           000 0 eng
*019  $bk
*08230$a616.8982
*100  $aLindström, Eva$4aut$_76235200
*245  $aA pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden
*300  $aS. [403]-413 : ill.
*500  $aVitenskapelig artikkel
*650  $aPsykofarmaka$2norart$_18181100
*650  $alegemiddeløkonomi$9nor$2norart$_136386000
*650  $aschizofreni$9nor$2norart$_128828500
*653  $aantipsychotics$9eng$_131461900
*653  $acost-effectiveness$9eng$_136386100
*653  $acost-utility$9eng$_136386200
*653  $apharmacoeconomics$9eng$_136386300
*653  $aschizophrenia$9eng$_128835300
*700  $aEberhard, Jonas;$4aut$_136386400
*700  $aFors, Björn M.;$4aut$_136386500
*700  $aHansen, Karina;$4aut$_136386600
*700  $aSapin, Christophe$4aut$_136386700
*773  $tNordic journal of psychiatry$gVol. 65, nr. 6 (2011)$x0803-9488$w(NO-LaBS)36505(tnr)
*8564 $uhttps://doi.org/10.3109/08039488.2011.590603
*999  $z1100504480$anorart:1100504480
^